List of Schedule V drugs (US)

From Wikipedia, the free encyclopedia

This is the list of Schedule V drugs as defined by the United States Controlled Substances Act.[1] The following findings are required for drugs to be placed in this schedule:[2]

  1. The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
  2. The drug or other substance has a currently accepted medical use in treatment in the United States.
  3. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.

The complete list of Schedule V drugs follows.[1] The Administrative Controlled Substances Code Number for each drug is included.

Opiates and opioids[]

ACSCN Drug
N/A Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams
N/A Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams
N/A Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams
N/A Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit
N/A Not more than 100 milligrams of opium per 100 milliliters or per 100 grams
N/A Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit

Stimulants[]

ACSCN Drug
1485 Pyrovalerone (including the positional isomer, α-PHiP)

Cannabinoids[]

ACSCN Drug
1485 Cannabidiol, only in a marijuana-derived pharmaceutical formulation marketed by GW Pharmaceuticals as Epidiolex. Cannabidiol derived from industrial hemp remains schedule 1.[3]

Others[]

ACSCN Drug
2710 Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide))
2779 Ezogabine (N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester)
2746 Lacosamide ([R]-2-acetoamido-N-benzyl-3-methoxy-propionamide)
2790 Lasmiditan (2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide)
2782 Pregabalin ([S]-3-(aminomethyl)-5-methylhexanoic acid]

References[]

  1. ^ a b 21 CFR 1308.15 (CSA Sched V) with changes through 77 FR 64032 (Oct 18, 2012). Retrieved September 6, 2013.
  2. ^ 21 U.S.C. § 812(b)(5) retrieved October 7, 2007
  3. ^ "Why This Colorado Law Firm is Upset over DEA's Rescheduling of CBD Medication".
Retrieved from ""